Novartis To Alert EU Doctors About Liver Failure Deaths In Zolgensma Patients
The European Medicines Agency’s pharmacovigilance committee has reviewed the updated advice that EU prescribers will get on enhanced monitoring of spinal muscular atrophy patients treated with Zolgensma following fatal cases of acute liver failure.
You may also be interested in...
Zolgensma should receive a conditional approval, says the European Medicines Agency’s drug evaluation committee, the CHMP.
Stay current on regulatory guidelines from around the world with Medtech Insight's Guidance Tracker. Forty-eight documents have been posted on the tracker since its last update.
A new EU guideline addresses numerous questions raised by study sponsors on processes for protecting commercial and personal data while using the Clinical Trials Information System.